Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
about
Pharmacological inhibition of dynamin II reduces constitutive protein secretion from primary human macrophagesAltered nitric oxide production mediates matrix-specific PAK2 and NF-κB activation by flowVascular Smooth Muscle Cells in Atherosclerosis.Flow-dependent cellular mechanotransduction in atherosclerosis.The arterial microenvironment: the where and why of atherosclerosis.α5β1 integrin signaling mediates oxidized low-density lipoprotein-induced inflammation and early atherosclerosis.Alternative splicing of endothelial fibronectin is induced by disturbed hemodynamics and protects against hemorrhage of the vessel wallThe double-edged sword of fibronectin in atherosclerosisEndothelial-to-mesenchymal transition drives atherosclerosis progression.Protocatechuic aldehyde inhibits TNF-α-induced fibronectin expression in human umbilical vein endothelial cells via a c-Jun N-terminal kinase dependent pathwayAnalysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis.Systematic analysis of the molecular mechanism underlying atherosclerosis using a text mining approachFibronectin contributes to pathological cardiac hypertrophy but not physiological growthThe RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translationFlow patterns regulate hyperglycemia-induced subendothelial matrix remodeling during early atherogenesis.Haemodynamics Regulate Fibronectin Assembly via PECAM.Interaction between integrin α5 and PDE4D regulates endothelial inflammatory signalling.Molecular biology of atherosclerosis.The Interaction between the Third Type III Domain from Fibronectin and Anastellin Involves β-Strand Exchange.Endothelial fluid shear stress sensing in vascular health and disease.Blood Brothers: Hemodynamics and Cell-Matrix Interactions in Endothelial Function.Tenascin-C is increased in atherothrombotic stroke patients and has an anti-inflammatory effect in the human carotid artery.Integrin signaling in atherosclerosis.The two-component system VicRK regulates functions associated with Streptococcus mutans resistance to complement immunity.αvβ3 Integrins Mediate Flow-Induced NF-κB Activation, Proinflammatory Gene Expression, and Early Atherogenic Inflammation.Expression Profiling of Genes Related to Endothelial Cells Biology in Patients with Type 2 Diabetes and Patients with Prediabetes.Differential regulations of fibronectin and laminin in Smad2 activation in vascular endothelial cells in response to disturbed flow.Inhibiting Integrin α5 Cytoplasmic Domain Signaling Reduces Atherosclerosis and Promotes Arteriogenesis.Stimulatory effects of advanced glycation endproducts (AGEs) on fibronectin matrix assembly.Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation.Chlorination and oxidation of human plasma fibronectin by myeloperoxidase-derived oxidants, and its consequences for smooth muscle cell function
P2860
Q27334065-9D19092E-90C7-4DEF-A7CC-71A498C37B3BQ28394043-99FA6463-E27B-4F57-ACA9-AD79B60FFEEEQ30277316-021F18C4-1C4B-41E2-A4CE-2DC0D2F17C48Q30409536-3820E192-DD3E-47A2-AC8B-E1CBE3A2191BQ33619657-495D6148-37D5-4140-9465-46D9F194568FQ33896730-B29B41E6-FDE6-40D6-BD4E-6DE2CD97651CQ34076187-0F28ABEB-2987-4B81-B7E7-EC9FECE0EB86Q36126242-584EF76C-5F59-40F9-B527-11CE7DBB2E08Q36335841-39D695DF-558D-473B-AEF6-B3203944CFB6Q36502669-53F3D80A-6135-4ACD-AE38-3C6A31005B0AQ36943033-994B6E41-EA65-4870-A46D-77424BF163F3Q36960706-EFD54E0B-DC99-4CD2-9861-3FA89880DF75Q37268923-265FB2A3-6CBC-4F4A-9A5F-8A5E351F31A3Q37315134-01483295-B5FF-46BD-9389-F87071284954Q37526511-C691885B-A0AE-4A1D-9D47-524778CFC6C5Q37605148-2E4EFECD-11BB-4A3C-AE47-63E019F36357Q37634928-56635A0D-CF10-4068-9E7E-78F33A5468E1Q38125279-51919456-23F7-40FA-AEA2-2D9F3DD72D2CQ38618635-3E95BC7E-83BE-4AB4-8629-3ADE6A983D49Q38630594-F0D5AE18-391E-493D-907D-71E2C7B5B7D7Q38926872-E9F460D6-0C40-45C0-940F-16501C583CB9Q38947769-56AF5557-BE28-48B1-B07D-AF25D128A336Q39155496-0612C938-AB82-4185-897E-1F1E203B7E2FQ40262634-5597CD4B-6427-4A6E-8360-EF23BFA11D61Q41138735-3391ED73-DC84-488D-A6C1-6EF8AC15E615Q41984090-755FCC99-07D5-4726-87DC-EEA08218622CQ47129261-B8225B74-A4B9-42D4-A855-0FFD579175DEQ49572104-347E5AAB-9CCC-4EAE-8B0D-A6776DC0F4D5Q51636281-1B950B27-D442-47E5-B7DA-6D307BFA48CDQ52559215-DDDDCEDE-C860-45C6-8D63-A7AAA1B107DDQ58762763-D9A71C04-B59A-49DA-8249-74791DFED799
P2860
Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Plasma fibronectin deficiency ...... sion and fibrous cap formation
@en
Plasma fibronectin deficiency ...... sion and fibrous cap formation
@nl
type
label
Plasma fibronectin deficiency ...... sion and fibrous cap formation
@en
Plasma fibronectin deficiency ...... sion and fibrous cap formation
@nl
prefLabel
Plasma fibronectin deficiency ...... sion and fibrous cap formation
@en
Plasma fibronectin deficiency ...... sion and fibrous cap formation
@nl
P2093
P2860
P356
P1476
Plasma fibronectin deficiency ...... sion and fibrous cap formation
@en
P2093
Eloi Montanez
Eva Bengtsson
Ina Rohwedder
Jan Nilsson
Karsten Beckmann
Oliver Soehnlein
Pontus Dunér
P2860
P304
P356
10.1002/EMMM.201200237
P577
2012-04-19T00:00:00Z